Background Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective To …

Background The influence of comorbidities on the efficacy and safety of biologic therapies in
psoriasis has not been rigorously explored. Objective To assess the incremental burden of …

Background: Secukinumab is an anti-IL-17A monoclonal antibody approved for the
treatment of moderate-to-severe psoriasis in adult patients. Despite its favourable safety and …

Background Secukinumab is a fully human monoclonal antibody that selectively binds to
and neutralizes interleukin‐17A. Objectives To assess the efficacy and safety of different …

Introduction There is limited evidence to guide clinicians on the treatment of psoriasis with
biologics in patients with a history of malignancy who are often excluded from clinical trials …

Background Long-term real-life data on secukinumab use in psoriasis are limited. Objectives
Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in …

Background Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has
demonstrated efficacy and safety in patients with moderate to severe plaque psoriasis …

Treatment of moderate to severe psoriasis often requires systemic therapy, including
biologics. Partial response to biologics and relapses are commonly managed with dose …

Secukinumab is a fully human monoclonal antibody that can selectively neutralize
interleukin‐17A, and its excellent efficacy has been demonstrated in clinical trials for …

Objectives: To evaluate efficacy and safety of the anti-IL-17 drug secukinumab in a real-life
large cohort of patients with moderate-to-severe plaque psoriasis in Central Italy. Methods …